Experimental approaches: Multiple monitored ECT (MMECT)
Effectiveness not established
Experimental approaches: Ultrabrief bilateral ECT
Listed as experimental in policy
Experimental approaches: Adjunctive ketamine in ECT
Effectiveness not established; evidence mixed
Experimental approaches: Functional MRI of fronto-temporal connectivity to predict ECT outcome
Not established for clinical use
Experimental approaches: Measurement of plasma BDNF as an indicator of ECT response
Predictive value not established
Experimental indications: ECT for the following indications: addictive disorders (e.g., methamphetamine dependence), autism spectrum disorders, autoimmune encephalitis (eg, anti-NMDA receptor encephalitis), body dysmorphic disorder, complex regional pain syndrome, delirium, dementia-associated agitation and aggression, drug-resistant epilepsy, eating disorders, Lennox-Gastaut syndrome, motor symptoms of Parkinson disease, neuropsychiatric complications of COVID-19, obsessive-compulsive disorder, post‑traumatic stress disorder, refractory status epilepticus, self-injurious behaviors, somatic symptom disorder, tardive dyskinesias/tardive syndromes, Tourette syndrome, and treatment‑resistant schizophrenia.
List from policy; these uses are considered experimental/investigational
Experimental cognitive-enhancer strategies: Use of ketamine, liothyronine, melatonin, opioid receptor agonists, piracetam, and prophylactic cognitive enhancers (eg, cholinesterase inhibitors and memantine) to improve cognitive function during ECT
Effectiveness not established
Experimental EEG prediction: Use of EEG to predict clinical response to ECT in individuals with major depression
Not established for routine clinical use